Discovery of a series of potent, orally active α,α- disubstituted piperidine NK1 antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 21, 2010, Pages 6313-6315

  Xiao, Dong ^a   Wang, Cheng ^a   Palani, Anandan ^a   Tsui, Hon Chung ^a   Reichard, Gregory ^a   Paliwal, Sunil ^a   Shih, Neng Yang ^a   Aslanian, Robert ^a   Duffy, Ruth ^a   Lachowicz, Jean ^a   Varty, Geoffrey ^a   Morgan, Cynthia ^a   Liu, Fei ^a   Nomeir, Amin ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Dibasic amine metabolite; NK1 antagonist

Indexed keywords

AMIDE; DRUG METABOLITE; NEUROKININ 1 RECEPTOR ANTAGONIST; PIPERIDINE DERIVATIVE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CHEMICAL MODEL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG SYNTHESIS; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; RAT;

ANIMALS; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; GERBILLINAE; HALF-LIFE; PIPERIDINES; RATS; RECEPTORS, NEUROKININ-1; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77957872554     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.08.059     Document Type: Article

References (16)

1. S. Jones, and J.M. Gibbins Curr. Opin. Pharmacol. 8 2008 114
2. G. Alvaro, and R. Di Fabio Curr. Opin. Drug Discovery Dev. 10 2007 613
3. R.A. Duffy Exp. Opin. Emerg. Drugs 9 2004 9
4. J.S. Albert Exp. Opin. Ther. Pat. 14 2004 1412
5. T.M. Dando, and C.M. Perry Drugs 64 2004 777
6. T. Harrson, B.J. Willaims, and C.J. Swain Bioorg. Med. Chem. Lett. 4 1994 2733
7. D. Xiao, B.J. Lavey, A. Palani, C. Wang, R.G. Aslanian, J.A. Kozlowski, N.Y. Shih, A.T. McPhail, G.P. Randolph, J.E. Lachowicz, and R.A. Duffy Tetrahedron Lett. 46 2005 7653
8. D. Xiao, C. Wang, A. Palani, G. Reichard, R. Aslanian, N.-Y. Shih, and A. Buevich Tetrahedron: Asymmetry 17 2006 2596
9. G.I. Stevenson, A.M. MacLeod, I. Huscroft, M.A. Cascieri, S. Sadowski, and R. Baker J. Med. Chem. 38 1995 1264
10. i values were obtained using the Cheng and Prusoff equation. Cascieri, M. A.; Macleod, A. M.; Underwood, D.; Shiao, L. L.; Ber, E.; Sadowski, S.; Yu, H.; Merchant, K. J.; Swain, C. J.; Strader, C. D.; Fong, T. M. J. Biol. Chem. 1994, 269, 6587.
11. 1 antagonists were administered orally in 0.4% methylcellulose in distilled water at the dose indicated at various pretreatment times prior to injection of GR73632. Data are expressed as a percent decrease (% inhibition) in the amount of time spent foot tapping compared to vehicle-treated controls. Rupniak, N. M. J.; Williams, A. R. Eur. J. Pharmacol. 1994, 265, 179.
12. The rat PK assay was run at 10 mpk (unless otherwise specified) using oral dosing with 20% HPBCD as vehicle. AUC was determined from 0 to 6 h. For reference: Cox, K. A.; Dunn-Meynell, K.; Korfmacher, W. A.; Broske, L.; Nomeir, A. A.; Lin, C. C.; Cayen, M. N.; Barr, W. H. Drug Discovery Today 1999, 4, 232.
13. P. Bonaventure, M. Letavic, C. Dugovic, S. Wilson, L. Aluisio, C. Pudiak, B. Lord, C. Mazur, F. Kamme, S. Nishino, N. Carruthers, and T. Lovenberg Biochem. Pharmacol. 73 2007 1084
14. R.J. Gum, D. Hickman, J.A. Fagerland, M.A. Heindel, G.D. Gagne, J.M. Schmidt, M.R. Michaelides, S.K. Davidsen, and R.G. Ulrich Biochem. Pharmacol. 62 2001 1661
15. Z. Ruben, D.C. Dodd, K.J. Rorig, and S.N. Anderson Toxicol. Appl. Pharmacol. 97 1989 57
16. T.-L. Choi, A.K. Chatterjee, and R.H. Grubbs Angew. Chem., Int. Ed. 40 2001 1277